Hao Ming-Zhi, Lin Hai-Lan, Chen Qiang, Ye Yun-Bin, Chen Qi-Zhong, Chen Ming-Shui
Department of Interventional Radiology, Fujian Provincial Tumor Hospital, Fuzhou, Fujian 350014, PR China.
Chin J Cancer. 2010 Feb;29(2):172-7. doi: 10.5732/cjc.009.10410.
Cytokine-induced killer (CIK) cells have high anti-tumor activity for hepatocellular carcinoma (HCC). Whether CIK cell therapy can eradicate residual cancer cells and prevent or postpone tumor relapse after transcatheter arterial chemoembolization (TACE) should be testified. This study was to evaluate the efficacy of CIK cell therapy combined with TACE on HCC.
A total of 146 consecutive patients with unresectable HCC were divided into combination group (72 patients treated with CIK cell therapy combined with TACE) and TACE group (74 patients treated only with TACE). The progression-free survival (PFS) and overall survival (OS) were analyzed.
The 6-month, 1-year, and 2-year PFS rates were 72.2%, 40.4%, 25.3% in combination group, and 34.8%, 7.7%, 2.6% in TACE group. The median time to progression was 11 months [95% confidence interval (CI), 8-14 months] in combination group and 5 months (95% CI, 4-7 months) in TACE group. The estimated 6-month, 1-year, and 2-year OS rates were 90.3%, 71.9%, 62.4% in combination group, and 74.6%, 42.8%, 18.8% in TACE group. The median OS was 31 months (95% CI, 27-35 months) in combination group and 10 months (95% CI, 7-13 months) in TACE group. The times of TACE, ECOG performance status, and CIK cell therapy were independent prognostic factors for PFS and OS.
Adjuvant immunotherapy with CIK cells could greatly improve the efficacy of TACE on HCC, and plays an important role in prolonging the PFS and OS of HCC patients after TACE.
细胞因子诱导的杀伤（CIK）细胞对肝细胞癌（HCC）具有较高的抗肿瘤活性。CIK细胞疗法能否根除残留癌细胞并预防或推迟经动脉化疗栓塞术（TACE）后肿瘤复发有待证实。本研究旨在评估CIK细胞疗法联合TACE治疗HCC的疗效。
146例连续的不可切除HCC患者被分为联合组（72例接受CIK细胞疗法联合TACE治疗）和TACE组（74例仅接受TACE治疗）。分析无进展生存期（PFS）和总生存期（OS）。
联合组6个月、1年和2年的PFS率分别为72.2%、40.4%、25.3%，TACE组分别为34.8%、7.7%、2.6%。联合组的中位疾病进展时间为11个月[95%置信区间（CI），8 - 14个月]，TACE组为5个月（95%CI，4 - 7个月）。联合组估计的6个月、1年和2年OS率分别为90.3%、71.9%、62.4%，TACE组分别为74.6%、42.8%、18.8%。联合组的中位OS为31个月（95%CI，27 - 35个月），TACE组为10个月（95%CI，7 - 13个月）。TACE次数、东部肿瘤协作组（ECOG）体能状态和CIK细胞疗法是PFS和OS的独立预后因素。
CIK细胞辅助免疫疗法可显著提高TACE治疗HCC的疗效，对延长TACE术后HCC患者的PFS和OS起重要作用。
